Literature DB >> 10354199

Muscle creatine phosphate in gyrate atrophy of the choroid and retina with hyperornithinaemia--clues to pathogenesis.

K Heinänen1, K Näntö-Salonen, M Komu, M Erkintalo, O J Heinonen, K Pulkki, M Valtonen, E Nikoskelainen, A Alanen, O Simell.   

Abstract

BACKGROUND: In gyrate atrophy of the choroid and retina with hyperornithinaemia (GA), inherited deficiency of ornithine-o-aminotransferase leads to progressive fundus destruction and atrophy of type II skeletal muscle fibres. Because high ornithine concentrations inhibit creatine biosynthesis, the ensuing deficiency of high-energy creatine phosphate may mediate the pathogenesis.
MATERIALS AND METHODS: Relative concentrations of inorganic phosphate (Pi), creatine phosphate (PCr) and ATP in resting calf muscle were recorded in 23 GA patients and 33 control subjects using 31P-magnetic resonance spectroscopy (MRS). Eight patients with autosomal recessive retinitis pigmentosa with matched control subjects constituted an additional reference group.
RESULTS: The PCr/Pi and PCr/ATP ratios (means +/- SD) were lower for the GA patients than for healthy control subjects [4.66 +/- 0.37 vs. 9.75 +/- 2.17 (P < 0.0001) and 2.85 +/- 0.37 vs. 3.70 +/- 0.50 (P < 0.05) respectively]. In retinitis pigmentosa the respective values were 9.12 +/- 2.57 and 4.25 +/- 0.45. Age and stage of the disease had no effect.
CONCLUSION: Muscle 31P-MRS spectra were markedly abnormal in all GA patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10354199     DOI: 10.1046/j.1365-2362.1999.00467.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

1.  Oral lysine feeding in gyrate atrophy with hyperornithinaemia--a pilot study.

Authors:  K Peltola; O J Heinonen; K Näntö-Salonen; K Pulkki; O Simell
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

2.  Creatine metabolism in urea cycle defects.

Authors:  Sara Boenzi; Anna Pastore; Diego Martinelli; Bianca Maria Goffredo; Arianna Boiani; Cristiano Rizzo; Carlo Dionisi-Vici
Journal:  J Inherit Metab Dis       Date:  2012-05-30       Impact factor: 4.982

Review 3.  Creatine supplementation in health and disease: what is the evidence for long-term efficacy?

Authors:  Wim Derave; Bert O Eijnde; Peter Hespel
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

4.  Osteoporosis associated with gyrate atrophy: a case report.

Authors:  Isik Ahmet; Koca Suleyman Serdar
Journal:  Doc Ophthalmol       Date:  2006-08-12       Impact factor: 2.379

5.  Central nervous system involvement in gyrate atrophy of the choroid and retina with hyperornithinaemia.

Authors:  M Valtonen; K Näntö-Salonen; S Jääskeläinen; K Heinänen; A Alanen; O J Heinonen; N Lundbom; M Erkintalo; O Simell
Journal:  J Inherit Metab Dis       Date:  1999-12       Impact factor: 4.982

6.  CRISPR correction of the Finnish ornithine delta-aminotransferase mutation restores metabolic homeostasis in iPSC from patients with gyrate atrophy.

Authors:  Rocio Maldonado; Sami Jalil; Timo Keskinen; Anni I Nieminen; Mervi E Hyvönen; Risto Lapatto; Kirmo Wartiovaara
Journal:  Mol Genet Metab Rep       Date:  2022-04-01

Review 7.  Creatine Supplementation in Children and Adolescents.

Authors:  Andrew R Jagim; Chad M Kerksick
Journal:  Nutrients       Date:  2021-02-18       Impact factor: 5.717

8.  A neonate with ornithine aminotransferase deficiency; insights on the hyperammonemia-associated biochemical phenotype of gyrate atrophy.

Authors:  Aneta Kaczmarczyk; Mark Baker; Julianna Diddle; Tatiana Yuzyuk; David Valle; Kristin Lindstrom
Journal:  Mol Genet Metab Rep       Date:  2022-03-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.